Novartis and MMV Report Positive Results for Next-Generation Antimalarial Therapy

Novartis and Medicines for Malaria Venture have reported positive results from the Phase IIb study, evaluating a new non-artemisinin combination to treat uncomplicated malaria in children.

Novartis and Medicines for Malaria Venture (MMV) have reported, in a Sep. 29, 2021 press release, positive results from the Phase IIb study, evaluating a new non-artemisinin combination to treat uncomplicated malaria in children.

The Phase IIb study, which was conducted in children less than 12 years of age, evaluated a novel agent, ganaplacide, in combination with a new formulation of lumefantrine that has been optimized for once daily dosing. This novel combination therapy has the potential to clear malaria infection and block the transmission of the malaria parasite.

“The world needs a diversified pipeline of anti-malarial medicines, especially as we are faced with emerging resistance to current treatments,” said Sujata Vaidyanathan, head Global Health Development Unit, Novartis, in the press release. “These results are definitely good news, but much more work remains.”

“This is a truly exciting step forward in the development of next-generation antimalarials,” added David Reddy, CEO of MMV, in the press release. “With this Phase IIb data we remain cautiously optimistic that ganaplacide/lumefantrine could one day be saving the lives of those at greatest risk of malaria—young children. MMV is proud to have partnered with Novartis in this project right from the discovery of the compound through to its clinical development and look forward to the next steps.”

Source: Novartis